Skip to content
10-Q

Quarterly Report

Monte Rosa Therapeutics, Inc. GLUE

0001193125-26-210358

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 84.48M sh
Shares Diluted Q1 2026 · Mar 31, 2026 99.88M sh
Shares Diluted Q1 2026 · Mar 31, 2025 82.96M sh
Dividends Paid Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2026 $1.87M
Capex Q1 2026 · Mar 31, 2025 $1.59M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$37.37M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$45.49M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $159.86M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $129.88M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $78.53M
Stockholders Equity Q1 2026 · Mar 31, 2026 $521.92M
Stockholders Equity Q1 2026 · Dec 31, 2025 $233.06M
Stockholders Equity Q1 2026 · Mar 31, 2025 $275.16M
Stockholders Equity Q1 2026 · Dec 31, 2024 $222.94M
Current Liabilities Q1 2026 · Mar 31, 2026 $71.04M
Current Liabilities Q1 2026 · Dec 31, 2025 $64.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $214.51M
Total Liabilities Q1 2026 · Dec 31, 2025 $215.6M
Current Assets Q1 2026 · Mar 31, 2026 $677.55M
Current Assets Q1 2026 · Dec 31, 2025 $393.19M
Total Assets Q1 2026 · Mar 31, 2026 $736.43M
Total Assets Q1 2026 · Dec 31, 2025 $448.66M
Sga Expense Q1 2026 · Mar 31, 2026 $10.18M
Sga Expense Q1 2026 · Mar 31, 2025 $8.7M
Rd Expense Q1 2026 · Mar 31, 2026 $44.07M
Rd Expense Q1 2026 · Mar 31, 2025 $32.19M
Net Income Q1 2026 · Mar 31, 2026 −$44.5M
Net Income Q1 2026 · Dec 31, 2025 −$38.6M
Net Income Q1 2026 · Mar 31, 2025 $46.89M
Operating Income Q1 2026 · Mar 31, 2026 −$50.03M
Operating Income Q1 2026 · Mar 31, 2025 $44.04M
Revenue Q1 2026 · Mar 31, 2026 $4.21M
Revenue Q1 2026 · Mar 31, 2025 $84.93M